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Active speciﬁc immunotherapy is a promising ﬁeld in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3,
have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-
NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated
NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-
gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on
the relevance of prioritization of cancer antigens in vaccine development is also included.
1.Ganglioside-BasedCancerVaccines
The ﬁeld of cancer vaccines deﬁnitively changed after April
2010 when the US Food and Drug Administration (FDA)
approved Provenge (sipuleucel-T), a vaccine for advanced
prostate cancer patients [1]. For the ﬁrst time sipuleucel-
T convincingly increased overall survival by about four
months in a randomized Phase III trial conducted in 512
patients. While this immunotherapeutic agent is relatively
inconvenientasapersonalizedvaccine,itseemsthatselecting
the recombinant version of the prostatic acid phosphatase
(PAP)—expressed in 95% of prostatic tumor cells—as
antigen was critical [2], reaﬃrming target selection as a key
feature in cancer vaccine design.
Reasoning in the same way, gangliosides, a broad family
of structurally related glycolipids, were ﬁrstly suggested as
potential targets for cancer immunotherapy [3, 4]b a s e do n
their higher abundance in tumors when compared with the
matched normal tissues. Disappointingly, at the beginning
of the present century the failure of the best developed
ganglioside-based cancer vaccine for that time, GMK [5],
irradiated an unfavorable risky perception to all the projects
intheﬁeld,eventhosenotrelatedwiththetargetantigen,the
GM2 ganglioside.
Nevertheless, in these days ganglioside cancer vacci-
nologists were facing a kind of “polarization” of posi-
tions in view of new facts. Eggermont et al. reported an
earlier stop of the Phase III GMK vaccine clinical trial
in stage II melanoma patients because the Independent
Data Monitoring Committee detected an inferior survival
rate for the vaccine arm [6]. While diﬃcult to interpret
with respect to potential detrimental eﬀects, this result was
considered as a signiﬁcant setback for ganglioside-based
speciﬁc immunotherapy in melanoma. In the opposite side,
amoreoptimistic outlookofgangliosidesastargetsforactive
immunotherapy of cancer came from the recent work by
Cheever et al., who reported in 2009 the National Cancer
Institute pilot project for prioritization of cancer antigens
[7]. From the selected 75 representative antigens, 4 were
gangliosides (GD2, GD3, fucosyl-GM1, and N-acetyl-GM3),
ranking between positions 12 and 48.
As an overall, at the present moment only two N-
glycolyl (NGc) ganglioside-based vaccines, the focus of this
paper, are currently tested in Phase III clinical trials [8].2 Clinical and Developmental Immunology
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Figure 1: NGc gangliosides in human tumor biology. Although NGcGM3 is practically undetectable in healthy human tissues as a result of
an Alu-mediated inactivation of the gene, the ganglioside is highly expressed in several human cancer cells presumably due to incorporation
of dietary NGc.
These include racotumomab (formerly known as 1E10)
and NGcGM3/VSSP vaccine (Table 1). Racotumomab is
an anti-idiotype murine monoclonal antibody (mAb) to
NGc-containing gangliosides. An anti-idiotype mAb, such as
racotumomab, is the mirror image of the original antibody
formed against speciﬁc surface antigens. Thus, anti-idiotype
antibodies can act as antigens, inducing a response against
the original antigen. On the other hand, the NGcGM3/VSSP
vaccine results from the conjugation of the ganglioside into
very small size proteoliposomes (VSSP) derived from N.
meningitidis.
2. NGc GangliosidesinTumor Biology
The most common sialic acids in mammals are N-
acetylneuraminic acid and N-glycolylneuraminic acid, usu-
ally found as terminal constituents of diﬀerent membrane
glycoconjugates such as the GM3 ganglioside. The only
structural diﬀerence between them consists of a single oxy-
gen atom at the C-5 position of N-glycolylneuraminic acid,
catalyzedbythecytidinemonophospho-N-acetylneuraminic
acidhydroxylase(CMAH)[9].Incontrasttomostmammals,
including our closest relatives: the great apes, NGc is
practically undetectable in healthy human tissues and ﬂuids
[10], since human cells lack the presence of CMAH [11]. It is
known that this absence is due to the loss of a 92-bp segment
in the exon 6, which results in a frameshift mutation of the
human gene by an Alu-mediated inactivation [12, 13]d a t e d
2.5–3 million years ago, prior to brain expansion during
human evolution [14, 15].
It is noteworthy that the monosialic acid ganglioside
NGcGM3 is highly expressed in several human cancer cells
[16]. Although initially it was suggested that NGc could
be expressed in human tissues by an alternative metabolic
pathway [17], nowadays plenty of evidence suggests that the
presence of this sialic acid in human cancer is the result
of the metabolic incorporation of dietary NGc [18, 19], as
illustrated in Figure 1. We reported that cultured mouse
tumor cells lacking CMAH expression are able to process
and incorporate NGc from diﬀerent sources such as bovine
serum, NGc-rich mucins, or puriﬁed N-glycolylneuraminicClinical and Developmental Immunology 3
Table 1: N-glycosylated (NGc) ganglioside-based cancer vaccines.
Vaccine Product description Target antigen Potential indications Clinical Phase
Racotumomab Anti-idiotype murine
mAb (1E10 antibody)
NGc-containing
gangliosides
Lung cancer
Breast cancer
Pediatric tumors?
Ongoing Phase III
NGcGM3/VSSP
Ganglioside
conjugated with
bacterial
proteoliposomes
NGcGM3 ganglioside Breast cancer
Melanoma Sarcoma? Ongoing Phase III
acid, thus, promoting the metastatic phenotype [20]. More-
over, genetically modiﬁed mice expressing a human-like
CMAHmutationshowednoendogenousNGc,asinhumans
[21].
The signiﬁcance of NGc overexpression in human cancer
is still under investigation. Taking into consideration that an
anti-NGc antibody response was detected in several cancer
patients, Varki [22] recently hypothesized that antibody-
mediated inﬂammation could facilitate tumor progression.
However, it is accepted that high titers of these antibodies
c a nk i l lt u m o rc e l l s[ 22]. In addition, experimental results
obtained by de Le´ on et al. indicated that growth-stimulating
features of the NGc on tumor cells can be explained by
immune system down modulation [23].
3. PreclinicalData
Our team analyzed the antitumor activity and the preclinical
toxicity of the mAb racotumomab and the NGcGM3/VSSP
vaccine using diﬀerent animal models. Considering that the
most important feature of an anti-idiotype mAb (Ab2) is
its biological eﬀect, racotumomab was evaluated in two syn-
geneic murine tumor models, the F3II mammary carcinoma
(BALB/c mice) and B16 melanoma (C57BL/6 mice). Both
cell lines are positive for the idiotype mAb P3 (Ab1), which
speciﬁcally reacts with NGc-containing gangliosides on cell
surface [24, 25]. In BALB/c mice, vaccination with several
intraperitoneal doses, at 14-day intervals of racotumomab
coupled to keyhole limpet hemocyanin in Freund’s adjuvant,
signiﬁcantly reduced subcutaneous tumor growth of F3II
mammarycarcinomacellsandtheformationofspontaneous
lung metastases [24]. Similarly, intravenous administration
of uncoupled racotumomab, as a biological response mod-
iﬁer, dramatically inhibited metastatic lung colonization by
B16 melanoma cells in C57BL/6 mice [24].
Vaccination with aluminum hydroxide-precipitated
racotumomab induced antimetastatic eﬀects in the 3LL-
D122 Lewis lung carcinoma, a poorly immunogenic and
highly metastatic model in C57BL/6 mice [37]. The eﬀect
was associated to T cell inﬁltration, enhancement of tumor
apoptosis, and reduction of new blood vessels formation in
lung nodules. The 3LL-D122 lung carcinoma is an antigen-
positive, validated model for the NGcGM3 ganglioside. The
model evidenced an increased expression of such speciﬁc
antigen from primary tumors to metastatic lesions [38].
Immunization with the NGcGM3/VSSP vaccine, prepared
either with synthetic or natural source-derived ganglioside,
showed similar immunogenicity proﬁles and antitumor
eﬀects in the 3LL-D122 model [38].
Racotumomab also demonstrated a potent antitumor
eﬀect in combination with chemotherapy in preclinical
studies, providing a rationale for chemo-immunotherapy
combinations in solid cancers. Administration of low-dose
cyclophosphamide together with subcutaneous immuniza-
tion with racotumomab in alum signiﬁcantly reduced F3II
tumor growth [25]. The antitumor response was comparable
to that obtained with standard high-dose chemotherapy in
such breast cancer model, but without overt signs of toxic-
ity. Interestingly, combinatory chemo-immunotherapy pro-
moted CD8+ lymphocyte tumor inﬁltration and increased
tumor apoptosis [25].
Ganglioside immunotherapies with racotumomab and
NGcGM3/VSSP vaccine were well tolerated in animals [24,
38]. In preclinical toxicology studies, the immunization
protocoldidnotaﬀectbodyweightgain,foodandwatercon-
sumption or induce other signs of overt toxicity in murine
models. Subacute toxicity after continuous daily treatment
was expressed by an excessive activation of extramedullary
myelopoiesis in the spleen and liver in all mice and a
strong inﬂammatory reaction in the lungs, showing dense
neutrophil inﬁltrates in the interalveolar septa [24].
4. Expressionof NGc in Human Tumors
Tumor-speciﬁc expression of NGc-containing gangliosides
in some human tumors suggests that the induction of
an eﬀective immune response against these antigens may
be useful for patients with antigen-positive tumors. The
ganglioside NGcGM3 has been described in human neo-
plasms, including breast carcinoma [33, 34] and melanoma
[31] ,b u ti su s u a l l yn o td e t e c t e di nn o r m a lh u m a nc e l l s .
This fact deﬁnes NGcGM3 as an interesting target for
immunotherapy.
As described by Tangvoranuntakul et al. [34] using a
monospeciﬁc antibody against NGc, staining showed cell
type-speciﬁc reactivity in adult human tissues. The overall
pattern of expression was summarized as prominent in
secretory epithelia and associated secretions and present in
many blood vessels. In addition, in fetal tissues NGc can
be detected in epithelial cells or secretions as well as the
placental villus blood vessels [34].
van Cruijsen et al. [35] assessed the possible association
of NGcGM3 expression with angiogenesis in lung cancer.
They examined 176 samples of nonsmall cell lung cancer4 Clinical and Developmental Immunology
Table 2: Relevant characteristics of NGcGM3 ganglioside as a cancer antigen, according to the antigen prioritization criteria described by
Cheever et al. [7].
Criteria Data on NGcGM3
Therapeutic function Clinical data showing that a vaccine-induced clinical responses in at least a small number
of patients [26–28]
Immunogenicity Tc e l l[ 29] and antibody [26, 27, 29, 30] responses elicited in clinical trials, spontaneous
antibody observed in some patients [31, 32]
Oncogenicity Increased expression in adult [31, 33–35] and pediatric [36] solid tumors, to be
determined a clear association with oncogenic process or tissue diﬀerentiation
Speciﬁcity Overexpressed in cancer with little or no expression in normal adult tissues [34]
Expression level and % positive cells Highly expressed on most cancer cells in patients designated for treatment [31, 33, 35, 36]
Stem cell expression Expression on most cancer cells [35, 36] but without information about putative stem
cells
No. of patients with antigen-positive cancers High level of expression in >80% of patients with a particular tumor type [35, 36]
No. of antigen epitopes Short antigenic segment with one or few epitopes [31]
Cellular location of antigen expression Expressed on the cell surface [31, 33, 35, 36] with little or no circulating antigen [10, 11]
(NSCLC) by immunohistochemistry in tissue microarray
and found that NGcGM3 is widely expressed in more
than 90% of the cases. Microvessel density, as determined
by CD34 staining, was lower in NSCLC tissues with high
NGcGM3 expression, suggesting that the presence of the
gangliosidemayfavoranantiangiogenicresponse.Moreover,
basedontheexpressionofCD83whichisamarkerofmature
dendritic cells, NGcGM3 appeared to be involved in tumor-
induced dendritic cell suppression [35].
More recently, Scursoni et al. [36] reported for the ﬁrst
time the expression of NGcGM3 in a pediatric solid tumor.
They detected the ganglioside in 88% of the cases of Wilms’
tumor (nephroblastoma), using the speciﬁc anti-NGcGM3
mAb 14F7 and a peroxidase-labeled polymer conjugated
to secondary antibodies on postchemotherapy samples.
Wilms tumor is considered an “embryonic tumor” of the
kidney, being a mimicry of various elements in normal or
abnormal nephrogenesis and presenting a diverse spectrum
of histologic appearance. In this regard, Wilms tumor gives
the unique opportunity to learn about the expression of
NGc gangliosides in diverse transformed cell lineages, com-
prising epithelial, stromal, and blastemal elements [39]. The
strongest expression was found in the epithelial component
of Wilms’ tumor, and the lower percentage of positive tumor
cellswasobservedinthestromalsubtype[36].Similarresults
were obtained in a preliminary study with P3, a less-speciﬁc
mAb that recognizes diﬀerent NGc-containing gangliosides
and sulfatides, including NGcGM3 [40]. More than 70% of
Wilms tumors showed a positive staining for NeuGc residues
using the P3 antibody [36].
5.ImmunologicalResponse toNGcinHumans
Targeting ganglioside antigens has been a matter of concern
due to the possibility of inducing autoimmune responses.
Indeed, in most neuropathies of immunological origin,
endogenous gangliosides have been shown to be the tar-
get of the autoimmune reactions [41–44]. Antiganglioside
antibodies may also aﬀect nonneural tissues, as occuring
in systemic lupus erythematosus [45], rheumatoid arthritis,
or Sjogren’s syndrome [41]. Antibodies reactive to NGc-
containing glycolipids have been found to be induced in
patients after repeated transfusions with sera from other
species [46], in rheumatoid arthritis [47], and also in
melanoma patients [32]. Melanoma cells express NGc-
containing gangliosides, including NGcGM3 [31], and natu-
ral anti-NGc antibodies are increased in melanoma patients.
Most interestingly, a signiﬁcantly higher level of anti-NGc
antibodies was demonstrated in those patients who were free
of disease more than 5 years after surgery than in those who
relapsed within 2 years [32].
In spite of what could be expected, no induction of
detrimental autoimmune reactions have been described over
decades of clinical development of cancer vaccines targeting
endogenous gangliosides such as GM2, GD2, and GD3.
In this respect, the heterophilic nature of NGcGM3 is
consideredanadditionalassetofthistumorantigen,since,as
reviewed in the following sections, the absence of signiﬁcant
expression in normal tissue allows for increased immune
responses to immunization while precluding self-targeted
reactions.
Breast cancer patients were treated with a regime of 5
biweekly IM injections of NGcGM3/VSSP vaccine followed
by monthly boosters. Anti-NGcGM3 IgM and IgG responses
were detected in all patients who completed the ﬁrst 5
injections,collectivelytermedas“inductionphase”.Thetime
course of antibody production showed an overall increase
across the 32-week followup, and the maximal recorded
titers reached 164,000 for both IgM and IgG. The functional
relevance of the induced antibodies was underscored by their
capacity to react against an NeuGcGM3+ murine tumor
cell line and mediated complement-dependent cytotoxic-
ity. Further conﬁrming their speciﬁcity for the targeted
ganglioside, the induced antibodies reacted as well with
human mammary ductal carcinoma cells without staining of
surrounding normal tissue [26].
In a second clinical trial, 21 advanced melanoma patients
received the same vaccination schedule [30]. Two dose levelsClinical and Developmental Immunology 5
were examined: 0.2 and 0.4mg of ganglioside per dose. The
immunogenicity of NGcGM3/VSSP was conﬁrmed, with
all evaluable patients eliciting IgM and IgG responses after
treatment. Antibody class switching to IgA was detected as
well. Delayed-type hypersensitivity (DTH) responses were
also evaluated with ID injections of NGcGM3/VSSP. DTH
responseswereobservedin46%ofpatientsatthe0.2mgdose
levelandin78%ofpatientsatthe0.4mgdoselevel.Thegan-
glioside contribution to the speciﬁcity of the hypersensitivity
reactions was, however, not assessed. No clear relationship
could be established between immunological response and
the clinical outcome, and the lower dose level was selected
forfutureclinicaldevelopmentduetoitssafertoxicityproﬁle
[30].
The immune response elicited by the murine anti-
idiotypicmAbracotumomabwasmonitoredingreaterdetail
andinadditionalclinicalsettings.Thevaccinationregimefor
racotumomab administration consisted of a 6-dose induc-
tion phase followed by monthly boosters. Anti-ganglioside
responses were induced in 16/17 melanoma patients [48],
16/16 breast cancer patients, and 16/20 NSCLC patients
[27]. The speciﬁcity of the induced Ab3 antibodies was
assessed by adsorption and analysis of the reactivity of the
nonadsorbed fraction. Adsorption with an isotype-matched
monoclonal antibody (IgG1) abrogated a small fraction of
the racotumomab-directed reactivity, which is an indication
of the immunodominance of the racotumomab idiotype
over the rest of the IgG1 molecule [27]. Most interestingly,
adsorption of Ab3 antibodies with racotumomab preserved
50 to 90% of the reactivity for NGcGM3 in the non-
adsorbed fraction, suggesting that the idiotype (Id)+/antigen
(Ag)+ and Id−/Ag+ speciﬁcities are present on separate
antibody molecules [48]. Such Id−/Ag+ antibodies could
reﬂect the activation of an autologous idiotypic cascade in
the patient’s immune system [27]. The antibodies induced
by racotumomab are NGc speciﬁc. No cross-reaction was
observed to NAcGM3 [48] .T h et i m ec o u r s eo fN G c G M 3 -
speciﬁc antibodies over 50 weeks in breast cancer patients
under racotumomab treatment showed sustained antibody
titers. Some patients had detectable ganglioside-speciﬁc IgG
only by week 30, suggesting that the extended vaccination
regime not only is undetrimental to the immune response,
b u ti sf a v o r a b l ef o rl a t er e s p o n d e r sa sw e l l[ 29].
As described for NGcGM3/VSSP vaccine, the anti-
bodies induced by racotumomab treatment reacted with
an NGcGM3+ murine tumor cell line. In addition,
racotumomab-induced antibodies were able to react with
NGcGM3+ lung carcinoma tissue sections [49]. No signiﬁ-
cant diﬀerences were found in the antibody response across
the dose levels examined (0.5, 1, and 2mg). Maximal titers
reached about 10,000 in the three dose levels for both IgM
and IgG, with no signiﬁcant diﬀerences in the titer means
between dose levels [29]. The 1mg dose level was chosen for
further clinical investigation [50].
NGcGM3-speciﬁc cellular responses were assessed in
racotumomab-treated breast cancer patients. Cryopreserved
peripheral blood mononuclear cells were challenged in vitro
with ganglioside-loaded, CD1d+, autologous monocyte-
derived dendritic cells, and the response was measured
with an interferon-γ immunospot assay. A low frequency of
ganglioside-speciﬁc interferon-γ-secreting cells was detected
in 5/13 patients. These cytokine responses were undetectable
at baseline and became detectable by weeks 14 to 42,
thereby conﬁrming the convenience of an extended vac-
cination schedule to elicit a ganglioside-speciﬁc response
[29].
6. ToxicityandPreliminaryClinicalOutcomes
The main toxicities observed in stage III/IV breast cancer
patients receiving the NGcGM3/VSSP vaccine (200μgp e r
dose) were erythema and induration at the injection site,
occasionally associated with mild pain and fever. In spite
of the fact that this trial was not adequate for eﬃcacy
assessments, a remarkable progression-free survival time was
observed in 2 patients with lung metastases [26]. Similarly,
in another trial in advanced cutaneous and ocular malignant
melanomas, 7 patients treated with the NGcGM3/VSSP
vaccine remained alive for more than 2 years after inclusion
in the study [30].
In stage III/IV melanoma patients administered with
biweekly doses of the anti-idiotype mAb racotumomab
(2mg per dose), the tolerance was satisfactory and no unex-
pected or serious adverse events were reported. The more
frequent adverse event was the local reaction with induration
and erythema at the injection site [48]. In a clinical trial in
patients with stage III/IV breast cancer, doses of 1 or 2mg of
racotumomab were well tolerated. There were no diﬀerences
between the two levels of doses tested in toxicity [50]. In
another Phase I trial, the toxicity proﬁle of racotumomab
was investigated using an extended vaccination protocol of 6
biweekly intradermal injections (induction phase), followed
by 10 monthly boosters (maintenance). Nineteen patients
with high-risk (stage III) or metastatic breast cancer were
vaccinated with diﬀerent dose levels of 0.5, 1, and 2mg.
Vaccination was relatively well tolerated; local skin reactions
grades I and II represented the most common adverse event
followed by mild ﬂu-like symptoms lasting for 1 to 2 days.
Similar safety results were observed with the 3 tested dose
levels [29].
In a compassionate-use basis study, 34 stage IIIb and
37 stage IV NSCLC patients were vaccinated with racotu-
momab, after receiving standard chemotherapy and radio-
therapy [28]. Patients were administered with 5 biweekly
injections of 1mg of racotumomab, other 10 doses at 28-
day intervals, and later the patients who maintained a good
performance status continued to be immunized at this same
time interval. No evidence of unexpected or serious adverse
eﬀects was reported. The median survival time of patients,
who entered the study with partial response or disease
stabilization and with a performance status (PS) 1 after the
ﬁrst line of chemo/radiotherapy, was 11.50 months since
the start of vaccination. In contrast, the median survival
time calculated for patients who started vaccination with
progressive disease and/or a PS2 was 6.50 months [28].
A statistically signiﬁcant correlation was observed between
anti-ganglioside response and survival time in a subset of6 Clinical and Developmental Immunology
20 NSCLC patients from this study. Nonresponder patients
(n = 4) had a median survival time of 6.35 months (95%
CI, 4.97–9.67 months), whereas patients who developed
IgG and/or IgM antibodies against NGcGM3 had a median
survival time of 14.26 months (95% CI, 5.95–17.3 months;
P<. 01, log rank) [27].
Even though NGcGM3 is a glycolipid, its heterophilic
expression allowed a speciﬁc immune response when
patients were immunized with either a conjugate vaccine
(i.e., NGcGM3/VSSP) or an anti-idiotype mAb targeting
NGc gangliosides (i.e., racotumomab). Evidence of an NGc-
speciﬁccytokineresponsewasobservedinsomefewpatients,
and its correlation with clinical outcomes remains to be
established. The absence of cross-reaction with endogenous
gangliosides is inline with the absence of autoimmune
toxicity and overall safety proﬁle of both conjugated vaccine
and the racotumomab mAb. On the other hand, high
titer ganglioside-speciﬁc antibody responses were observed
in most of the patients, in correlation with survival in
a group of NSCLC patients accrued after completion of
ﬁrst-line chemotherapy [27], as described above. The pos-
sible involvement of the induced antibodies in a protec-
tive antitumor activity is actively being pursued. Recent
sequencingandmodellingstudiessuggestthatracotumomab
might selectively induce Ab3 antibodies with conserved
germline sequences speciﬁc for heterophilic saccharide
antigens [51]. Randomized controlled trials are presently
underway and are expected to provide further insight into
the role of the induced immune response on the clinical
outcome.
In summary, the above-mentioned studies indicate that
both vaccines targeted to NGc gangliosides have acceptable
safety outcomes and are able to induce speciﬁc humoral
and cellular immune responses. The response to vaccination
seems to be stronger in those patients with lower tumor
burden, better performance status, and a good response
to previous oncospeciﬁc treatment. Also, preliminary evi-
dence suggested that these vaccines may have a positive
inﬂuence on survival in patients with immune response
to NGcGM3 antigen. The current Phase III trials that are
being conducted at present will give a deﬁnitive answer to
the potential clinical beneﬁts oﬀered by these therapeutic
vaccines. Furthermore, studies will be required to determine
the more eﬃcient combination with chemotherapy or other
immune interventions to prevail over the tumor-induced
immunosuppression.
7.Perspectives
This paper deals with NGc gangliosides—and particularly
NGcGM3—as a target for cancer immunotherapy. With the
numerous antigens that can be used in immunotherapy,
the decision-making process for researchers, hospitals, and
companies, in whether or not to invest resources in a
speciﬁc antigen, has been always a very complicated matter.
Fortunately, in a recent work by the National Cancer
Institute Translational Research Working Group, Cheever
et al. developed a method for prioritization of cancer
antigens paving the way to take more rational, informed
decisions [7]. Such work aimed to develop a priority-
ranked list of cancer vaccine target antigens based on
predeﬁned and preweighted objective criteria. An additional
aim was testing a new approach for prioritizing transla-
tional research opportunities based on an analytic hierarchy
process (AHP), a structured technique, and a mathemat-
ical model for dealing with complex decisions. Antigen
prioritization involved developing a list of “ideal” cancer
antigen criteria/characteristics, assigning relative weights to
those criteria using pairwise comparisons. The result of the
criteria weighting, in descending order, was as follows: (a)
therapeutic function, (b) immunogenicity, (c) role of the
antigen in oncogenicity, (d) speciﬁcity, (e) expression level
and percent of antigen-positive cells, (f) stem cell expression,
(g) number of patients with antigen-positive cancers, (h)
number of antigen epitopes, and (i) cellular location of
antigen expression.
Having that work as a reference, we rethought of our
experimentation with NGc, and, although is neither on the
scope of this paper nor our prerogative to position the
antigen in the ranking, we can aﬃrm that NGc somehow
matches all of the criteria considered (Table 2), at least
in some proportion—as described throughout this paper—
whose relative weight should be evaluated by panels of
external experts.
Some authors have recently enunciated the introduction
of potential biases in the National Cancer Institute Pilot
Project [52]. Lang et al. aﬃrmed that the methodology used
(AHP) is not well described and is subject to several sources
of possible bias, such as participant selection, number of
antigens chosen for prioritization, errors in rank order,
redundancy, and internal validity. First of all, we diﬀer with
Lang et al. in the fact that AHP is not well described, due
to being a very well-known technique properly used in a
wide variety of settings, including cancer clinical decisions
[53, 54]. Cheever et al. clearly described the method by citing
the popular work of Bhushan [55] and how AHP is used in
a web-based tool [56]. AHP is a powerful tool, used widely
in science, and, although it has had some detractors over
the years, Forman and Gass . carried out an in-depth paper
discussing and rebutting the academic criticisms of AHP
[57].
Furthermore, at the time of Cheever’s paper publication
no cancer vaccine had yet been approved by FDA. However,
recent approval of sipuleucel-T for men with advanced
prostate cancer, targeting PAP antigen, gave us a valuable
lesson on this matter [58]. Interestingly, PAP ranked 26
out of 75 antigens in the ranking of cancer antigen pilot
prioritization [7], conﬁrming its capacity to somehow “fore-
cast” those antigens more likely to be translated to patients.
Althoughtherankingisdynamic,giventhatprioritieschange
as knowledge accrues from new studies, we must reinforce
the idea that the associated lists of weighted criteria inform
investigators as to what experimental evidence is required
to advance antigens to higher priority levels. In this line,
thosecriteriahelpedustoevaluatethatNGcGM3ganglioside
comprised most if not all relevant characteristics as a cancer
antigen for vaccine development.Clinical and Developmental Immunology 7
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